+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Obesity Treatment Market - Global Forecast 2026-2032- Product Image
Obesity Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Obesity Treatment Market - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5460255
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Obesity Treatment Market is projected to reach USD 25.46 Billion in 2026. It is expected to continue growing at a CAGR of 15.64%, reaching USD 61.38 Billion by 2032.

Obesity treatment has moved from episodic weight-loss management to evidence-based chronic disease care. The World Health Organization reports that more than 1 billion people were living with obesity in 2022, including 879 million adults and 159 million children and adolescents, making the condition one of the most significant global health burdens.

Demand is being driven by rising cardiometabolic disease, broader clinical acceptance of anti-obesity medications, expanding bariatric and endoscopic options, and payer interest in reducing obesity-linked costs from type 2 diabetes, cardiovascular disease, sleep apnea, osteoarthritis, and certain cancers. Clinical guidelines increasingly position obesity management as long-term care that combines lifestyle intervention, pharmacotherapy, surgical evaluation, behavioral support, and continuous monitoring.

Transformative Shifts in Obesity Care

The obesity treatment landscape is undergoing a structural shift as GLP-1 receptor agonists and dual incretin therapies redefine clinical expectations for durable weight reduction. Landmark trial results, including cardiovascular risk reduction evidence for semaglutide in selected patients with obesity and established cardiovascular disease, have elevated obesity treatment from cosmetic weight loss to risk-based medical intervention.

At the same time, care delivery is becoming multidisciplinary. Nutrition therapy, behavioral health, remote monitoring, pharmacotherapy, bariatric surgery, and maintenance programs are increasingly integrated to improve adherence, minimize weight regain, and support long-term metabolic outcomes. Regulatory agencies and clinical societies are also emphasizing safety surveillance, patient selection, and continuity of care as demand for evidence-backed obesity treatment accelerates.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating obesity treatment by improving patient identification, risk stratification, treatment matching, and adherence support. AI-enabled analytics can mine electronic health records to identify patients with obesity-related complications who may benefit from pharmacotherapy, intensive lifestyle intervention, or bariatric evaluation.

The cumulative impact is strongest where AI supports clinical workflow rather than replacing clinician judgment. Predictive models, connected scales, digital coaching, and automated prior authorization tools can reduce friction in care pathways, while safeguards for bias, privacy, interoperability, and clinical validation remain essential. AI can also support real-world evidence generation by tracking persistence, adverse events, weight trajectories, and cardiometabolic outcomes across diverse patient populations.

Key Regional Insights

North America remains a high-value obesity treatment region due to elevated disease prevalence, strong specialist networks, and fast uptake of novel anti-obesity medications. CDC data show U.S. adult obesity prevalence at 40.3% for August 2021 to August 2023, sustaining demand for medical, surgical, behavioral, and digital interventions, while Canada continues to advance obesity as a chronic disease within guideline-led care. Europe is shaped by universal health systems, health technology assessment, and cost-effectiveness scrutiny, with Germany, France, Italy, Spain, and the United Kingdom balancing prevention priorities with access to advanced pharmacotherapy and bariatric services.

Asia-Pacific is expanding as urbanization, dietary change, and sedentary lifestyles increase obesity and diabetes risk, especially across China, India, Australia, Japan, and South Korea. Latin America, led by Brazil and Mexico, faces high obesity and diabetes burdens but uneven reimbursement and fragmented access to specialist care. The Middle East, particularly GCC markets, is prioritizing obesity because of high diabetes prevalence and national chronic disease strategies, while Africa is managing a dual burden of undernutrition and rising obesity in urban populations, increasing the need for scalable prevention, primary care screening, and affordable treatment pathways.

Key Group Insights

The G7 has the strongest concentration of advanced obesity treatment infrastructure, including clinical research capacity, reimbursement pathways, regulatory maturity, and specialist obesity care. The European Union supports harmonized drug regulation through the European Medicines Agency, while national health systems determine access and cost controls, making evidence generation, comparative effectiveness, and health-economic value critical for adoption.

BRICS countries combine very large patient pools with uneven access to specialist care, creating opportunities for scalable, lower-cost care models, local manufacturing, and primary care-led obesity management. ASEAN markets are influenced by rapid urbanization, nutrition transition, and growing diabetes prevalence, while GCC countries are investing in chronic disease management, digital health infrastructure, and premium healthcare services. NATO is not a health bloc, but its member countries increasingly view metabolic health as relevant to workforce readiness, healthcare system resilience, and long-term productivity.

Key Country Insights

The United States is the most commercially dynamic obesity treatment market because of high prevalence, strong drug adoption, employer interest, specialist capacity, and active debate on insurance coverage. Canada is advancing chronic disease-oriented obesity care through clinical guidelines and multidisciplinary services, while Mexico and Brazil face substantial obesity and diabetes burdens that support demand for accessible pharmacologic, surgical, nutritional, and lifestyle-based solutions.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are expanding obesity services under budget-sensitive public systems, with reimbursement tied to evidence, clinical prioritization, and health technology assessment. Russia presents a large population base with variable access to advanced therapies and specialist obesity management. China and India have enormous addressable populations and rising metabolic disease risk linked to urbanization and lifestyle change, while Japan, South Korea, and Australia show strong demand for clinically validated, guideline-aligned care models that integrate pharmacotherapy, digital support, and long-term monitoring.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based positioning that connects weight reduction with measurable metabolic, cardiovascular, functional, and quality-of-life outcomes. Commercial strategies should align with obesity as a chronic, relapsing disease requiring maintenance therapy, adherence support, individualized escalation, and long-term patient monitoring.

Organizations should expand partnerships with payers, employers, health systems, primary care networks, and digital health platforms to improve access and persistence. Investment in real-world evidence, safety monitoring, supply reliability, clinician education, culturally tailored care, and affordability will be critical as demand outpaces traditional obesity care capacity. Leaders should also prepare for stricter scrutiny around patient selection, long-term safety, discontinuation outcomes, and equitable access.

Research Methodology

This executive summary is developed through secondary research using publicly available, data-backed sources including WHO, CDC, national health agencies, regulatory bodies, peer-reviewed clinical trials, clinical guidelines, and official health system publications. Insights are triangulated across epidemiology, treatment adoption, regulatory activity, reimbursement trends, clinical outcomes, and regional healthcare infrastructure.

The methodology emphasizes verified facts, market-relevant interpretation, and cross-regional comparison. No unsupported market-sizing claims are used; conclusions are framed around documented disease burden, approved therapies, clinical evidence, real-world care dynamics, and observable healthcare system trends. Regional, group, and country insights are synthesized narratively to maintain clarity, and decision-useful context.

Conclusion

Obesity treatment is entering a new phase defined by chronic disease management, advanced pharmacotherapy, multidisciplinary care, and data-enabled patient engagement. The scale of global obesity, combined with clinical evidence linking treatment to broader health outcomes, is expanding the strategic importance of obesity care across healthcare systems.

Organizations that pair scientific credibility with access strategies, digital support, supply resilience, and long-term outcome measurement will be best positioned to capture growth while improving population health. Sustainable success will depend on demonstrating durable outcomes, supporting equitable access, and integrating obesity treatment into routine cardiometabolic care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Obesity Treatment Market, by Treatment Type
7.1. Introduction
7.2. Pharmacological Treatments
7.2.1. Appetite Suppressants
7.2.2. Lipase Inhibitors
7.2.3. GLP-1 Receptor Agonists
7.2.4. Combination Therapies
7.3. Surgical Treatments
7.3.1. Gastric Bypass
7.3.2. Sleeve Gastrectomy
7.3.3. Adjustable Gastric banding
7.3.4. Biliopancreatic Diversion with Duodenal switch
7.4. Device-Based Treatments
7.4.1. Intragastric Balloons
7.4.2. Endoscopic Sleeve Gastroplasty
7.4.3. Electrical Stimulation Systems
8. Obesity Treatment Market, by Route of Administration
8.1. Introduction
8.2. Oral
8.3. Injectable
8.4. Transdermal
9. Obesity Treatment Market, by Patient Age Group
9.1. Introduction
9.2. Adults
9.3. Elderly
9.4. Pediatric
10. Obesity Treatment Market, by Gender
10.1. Introduction
10.2. Male
10.3. Female
11. Obesity Treatment Market, by Obesity Type
11.1. Introduction
11.2. Class I (BMI 30-35)
11.3. Class II (BMI 35-40)
11.4. Class III (Severe/Morbid obesity, BMI =40)
12. Obesity Treatment Market, by Distribution Channel
12.1. Introduction
12.2. Offline
12.3. Online
13. Obesity Treatment Market, by End-User
13.1. Introduction
13.2. Hospitals & Clinics
13.3. Specialty Clinics
13.4. Weight Loss & Wellness Centers
14. Obesity Treatment Market, by Region
14.1. Europe
14.2. Asia-Pacific
14.3. North America
14.4. Latin America
14.5. Middle East
14.6. Africa
15. Obesity Treatment Market, by Group
15.1. NATO
15.2. G7
15.3. European Union
15.4. BRICS
15.5. ASEAN
15.6. GCC
16. Obesity Treatment Market, by Country
16.1. United States
16.2. China
16.3. Germany
16.4. Japan
16.5. India
16.6. United Kingdom
16.7. France
16.8. Canada
16.9. Italy
16.10. Australia
16.11. South Korea
16.12. Spain
16.13. Brazil
16.14. Russia
16.15. Mexico
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Novo Nordisk A/S
18.2. Eli Lilly and Company
18.3. WW International, Inc.
18.4. Amgen Inc.
18.5. Noom, Inc.
18.6. AstraZeneca PLC
18.7. Herbalife Ltd.
18.8. Hims & Hers Health, Inc.
18.9. Rhythm Pharmaceuticals, Inc.
18.10. Zealand Pharma A/S
18.11. Omada Health Inc.
18.12. Boston Scientific Corporation
18.13. IEH Biopharma LLC
18.14. Medifast, Inc.
18.15. Sanofi SA
18.16. Takeda Pharmaceutical Company Limited
18.17. Pfizer, Inc.
18.18. Viking Therapeutics, Inc.
18.19. Currax Pharmaceuticals LLC
18.20. ReShape Lifesciences, Inc.
18.21. AbbVie Inc.
18.22. Atkins Nutritionals, Inc.
18.23. BTL Aesthetics
18.24. C.H. Boehringer Sohn AG & Ko. KG
18.25. F. Hoffmann-La Roche Ltd
18.26. GlaxoSmithKline plc.
18.27. Johnson & Johnson Services, Inc.
18.28. Kellogg Company
18.29. Medtronic PLC
18.30. Merck & Co.
18.31. NutriSystem, Inc.
18.32. Olympus Corporation
List of Figures
FIGURE 1. GLOBAL OBESITY TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL OBESITY TREATMENT MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL OBESITY TREATMENT MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL OBESITY TREATMENT MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL OBESITY TREATMENT MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 11. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GENDER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GENDER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 19. GLOBAL OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL OBESITY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL OBESITY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL OBESITY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL OBESITY TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL OBESITY TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL OBESITY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL PHARMACOLOGICAL TREATMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL PHARMACOLOGICAL TREATMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL PHARMACOLOGICAL TREATMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL APPETITE SUPPRESSANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL APPETITE SUPPRESSANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL APPETITE SUPPRESSANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL LIPASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL LIPASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL LIPASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL GLP-1 RECEPTOR AGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL GLP-1 RECEPTOR AGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL GLP-1 RECEPTOR AGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL SURGICAL TREATMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL SURGICAL TREATMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL SURGICAL TREATMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL GASTRIC BYPASS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL GASTRIC BYPASS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL GASTRIC BYPASS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL SLEEVE GASTRECTOMY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL SLEEVE GASTRECTOMY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL SLEEVE GASTRECTOMY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL ADJUSTABLE GASTRIC BANDING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL ADJUSTABLE GASTRIC BANDING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL ADJUSTABLE GASTRIC BANDING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL BILIOPANCREATIC DIVERSION WITH DUODENAL SWITCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL BILIOPANCREATIC DIVERSION WITH DUODENAL SWITCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL BILIOPANCREATIC DIVERSION WITH DUODENAL SWITCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL DEVICE-BASED TREATMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL DEVICE-BASED TREATMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL DEVICE-BASED TREATMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL INTRAGASTRIC BALLOONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL INTRAGASTRIC BALLOONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL INTRAGASTRIC BALLOONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL ENDOSCOPIC SLEEVE GASTROPLASTY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL ENDOSCOPIC SLEEVE GASTROPLASTY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL ENDOSCOPIC SLEEVE GASTROPLASTY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL ELECTRICAL STIMULATION SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL ELECTRICAL STIMULATION SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL ELECTRICAL STIMULATION SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ADULTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ELDERLY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ELDERLY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ELDERLY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL MALE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL MALE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL MALE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL FEMALE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL FEMALE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL FEMALE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL CLASS I (BMI 30-35) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL CLASS I (BMI 30-35) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL CLASS I (BMI 30-35) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL CLASS II (BMI 35-40) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL CLASS II (BMI 35-40) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL CLASS II (BMI 35-40) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL CLASS III (SEVERE/MORBID OBESITY, BMI =40) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL CLASS III (SEVERE/MORBID OBESITY, BMI =40) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL CLASS III (SEVERE/MORBID OBESITY, BMI =40) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL WEIGHT LOSS & WELLNESS CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL WEIGHT LOSS & WELLNESS CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL WEIGHT LOSS & WELLNESS CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL OBESITY TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. EUROPE OBESITY TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. EUROPE OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 103. EUROPE OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 104. EUROPE OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 105. EUROPE OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2017-2032 (USD MILLION)
TABLE 106. EUROPE OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 107. EUROPE OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 108. EUROPE OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 109. EUROPE OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 110. EUROPE OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 111. EUROPE OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2017-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 123. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 125. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 126. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 127. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2017-2032 (USD MILLION)
TABLE 128. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 129. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 130. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 131. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 132. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 133. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 134. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 136. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 137. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 138. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2017-2032 (USD MILLION)
TABLE 139. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 140. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 141. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 142. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 143. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 144. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 145. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 146. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 147. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 148. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 149. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2017-2032 (USD MILLION)
TABLE 150. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 151. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 152. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 153. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 154. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 155. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 156. AFRICA OBESITY TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 157. AFRICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 158. AFRICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 159. AFRICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 160. AFRICA OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2017-2032 (USD MILLION)
TABLE 161. AFRICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 162. AFRICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 163. AFRICA OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 164. AFRICA OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 165. AFRICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 166. AFRICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 167. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 168. NATO OBESITY TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 169. NATO OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 170. NATO OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 171. NATO OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 172. NATO OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2017-2032 (USD MILLION)
TABLE 173. NATO OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 174. NATO OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 175. NATO OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 176. NATO OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 177. NATO OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 178. NATO OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 179. G7 OBESITY TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 180. G7 OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 181. G7 OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 182. G7 OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 183. G7 OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2017-2032 (USD MILLION)
TABLE 184. G7 OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 185. G7 OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 186. G7 OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 187. G7 OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 188. G7 OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 189. G7 OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2017-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 201. BRICS OBESITY TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 202. BRICS OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 203. BRICS OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 204. BRICS OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 205. BRICS OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2017-2032 (USD MILLION)
TABLE 206. BRICS OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 207. BRICS OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 208. BRICS OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 209. BRICS OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 210. BRICS OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 211. BRICS OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 212. ASEAN OBESITY TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 213. ASEAN OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 214. ASEAN OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 215. ASEAN OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 216. ASEAN OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2017-2032 (USD MILLION)
TABLE 217. ASEAN OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 218. ASEAN OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 219. ASEAN OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 220. ASEAN OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 221. ASEAN OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 222. ASEAN OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 223. GCC OBESITY TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 224. GCC OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 225. GCC OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 226. GCC OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 227. GCC OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2017-2032 (USD MILLION)
TABLE 228. GCC OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 229. GCC OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 230. GCC OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 231. GCC OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 232. GCC OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 233. GCC OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 234. GLOBAL OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 235. UNITED STATES OBESITY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 236. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 237. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 238. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 241. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 242. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 243. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 244. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 245. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 246. CHINA OBESITY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 247. CHINA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 248. CHINA OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 249. CHINA OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 250. CHINA OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2017-2032 (USD MILLION)
TABLE 251. CHINA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 252. CHINA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 253. CHINA OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 254. CHINA OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 255. CHINA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 256. CHINA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 257. GERMANY OBESITY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 258. GERMANY OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 259. GERMANY OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 260. GERMANY OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 261. GERMANY OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2017-2032 (USD MILLION)
TABLE 262. GERMANY OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 263. GERMANY OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 264. GERMANY OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 265. GERMANY OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 266. GERMANY OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 267. GERMANY OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 268. JAPAN OBESITY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 269. JAPAN OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 270. JAPAN OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 271. JAPAN OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 272. JAPAN OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2017-2032 (USD MILLION)
TABLE 273. JAPAN OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 274. JAPAN OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 275. JAPAN OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 276. JAPAN OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 277. JAPAN OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 278. JAPAN OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 279. INDIA OBESITY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 280. INDIA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 281. INDIA OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 282. INDIA OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 283. INDIA OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2017-2032 (USD MILLION)
TABLE 284. INDIA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 285. INDIA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 286. INDIA OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 287. INDIA OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 288. INDIA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 289. INDIA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 290. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 291. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 292. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 293. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 294. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2017-2032 (USD MILLION)
TABLE 295. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 296. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 297. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 298. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 299. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 300. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 301. FRANCE OBESITY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 302. FRANCE OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 303. FRANCE OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 304. FRANCE OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 305. FRANCE OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2017-2032 (USD MILLION)
TABLE 306. FRANCE OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 307. FRANCE OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 308. FRANCE OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 309. FRANCE OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 310. FRANCE OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 311. FRANCE OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 312. CANADA OBESITY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 313. CANADA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 314. CANADA OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 315. CANADA OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 316. CANADA OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2017-2032 (USD MILLION)
TABLE 317. CANADA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 318. CANADA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 319. CANADA OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 320. CANADA OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 321. CANADA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 322. CANADA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 323. ITALY OBESITY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 324. ITALY OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 325. ITALY OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 326. ITALY OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 327. ITALY OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2017-2032 (USD MILLION)
TABLE 328. ITALY OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 329. ITALY OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 330. ITALY OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 331. ITALY OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 332. ITALY OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 333. ITALY OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 334. AUSTRALIA OBESITY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 335. AUSTRALIA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 336. AUSTRALIA OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 337. AUSTRALIA OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 338. AUSTRALIA OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2017-2032 (USD MILLION)
TABLE 339. AUSTRALIA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 340. AUSTRALIA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 341. AUSTRALIA OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 342. AUSTRALIA OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 343. AUSTRALIA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 344. AUSTRALIA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 345. SOUTH KOREA OBESITY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 346. SOUTH KOREA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 347. SOUTH KOREA OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 348. SOUTH KOREA OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 349. SOUTH KOREA OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2017-2032 (USD MILLION)
TABLE 350. SOUTH KOREA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 351. SOUTH KOREA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 352. SOUTH KOREA OBESITY TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 353. SOUTH KOREA OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2017-2032 (USD MILLION)
TABLE 354. SOUTH KOREA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 355. SOUTH KOREA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 356. SPAIN OBESITY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE

Companies Mentioned

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • WW International, Inc.
  • Amgen Inc.
  • Noom, Inc.
  • AstraZeneca PLC
  • Herbalife Ltd.
  • Hims & Hers Health, Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Zealand Pharma A/S
  • Omada Health Inc.
  • Boston Scientific Corporation
  • IEH Biopharma LLC
  • Medifast, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Pfizer, Inc.
  • Viking Therapeutics, Inc.
  • Currax Pharmaceuticals LLC
  • ReShape Lifesciences, Inc.
  • AbbVie Inc.
  • Atkins Nutritionals, Inc.
  • BTL Aesthetics
  • C.H. Boehringer Sohn AG & Ko. KG
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc.
  • Johnson & Johnson Services, Inc.
  • Kellogg Company
  • Medtronic PLC
  • Merck & Co.
  • NutriSystem, Inc.
  • Olympus Corporation

Table Information

Report AttributeDetails
No. of Pages186
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 25.46 Billion
Forecasted Market Value ( USD ) by 2032 $ 61.38 Billion
Compound Annual Growth Rate15.6%
Regions CoveredGlobal
No. of Companies Mentioned32

Related Topics

Related Reports

Obesity Diagnosis & Treatment Market - Global Forecast 2026-2032 - Product Image

Obesity Diagnosis & Treatment Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Anti-Obesity Therapeutics Market - Global Forecast 2026-2032 - Product Image

Anti-Obesity Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Digital Health for Obesity - Global Strategic Business Report - Product Image

Digital Health for Obesity - Global Strategic Business Report

  • Report
  • 281 Pages
  • Global
From
Global Digital Health For Obesity Market Size, Share & Industry Analysis Report By Component (Services, Software, and Hardware), By End-use (Patients, Providers, Payers, and Other End-use.), By Regional Outlook and Forecast, 2025 - 2032 - Product Image

Global Digital Health For Obesity Market Size, Share & Industry Analysis Report By Component (Services, Software, and Hardware), By End-use (Patients, Providers, Payers, and Other End-use.), By Regional Outlook and Forecast, 2025 - 2032

  • Report
  • 358 Pages
  • Global
From
Obesity-Related Cancer Market - Strategic Insights and Forecasts (2026-2031) - Product Image

Obesity-Related Cancer Market - Strategic Insights and Forecasts (2026-2031)

  • Report
  • 149 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.